![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS CARDIOLOGY FORUM
Minerva Medica 2010 August;101(4):215-38
Copyright © 2010 EDIZIONI MINERVA MEDICA
language: English
Antithrombotic treatment in acute coronary syndromes
Hoole S. P., Saw J. ✉
Division of Cardiology Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
Platelet activation and thrombin formation are integral in the pathophysiology of acute coronary syndrome. Currently available pharmacotherapies inhibit the cascade of platelet aggregation and activation, and prevent thrombin formation to limit platelet-fibrin complex formation, thus maintaining coronary patency and ultimately improving clinical outcomes. This is a rapidly evolving field with next-generation antithrombotic combinations aimed at achieving the “Holy Grail” of improved anti-ischemic efficacy whilst minimizing bleeding risk. Our review article focuses on the use of antithrombotic agents for the contemporary management of patients with ACS.